Loading...
Talaris Therapeutics, Inc.
TALS•NASDAQ
Healthcare
Biotechnology
$2.72
$-0.02(-0.73%)

Talaris Therapeutics, Inc. (TALS) Balance Sheet Analysis
Talaris Therapeutics, Inc. (TALS) manages its money wisely, with plenty of N/A and N/A to cover its bills. The company’s long-term debts are N/A, balanced by steady 0.00%. Shareholders’ stake in the business has shrunk. Overall, the numbers show a stable position, giving it room to invest, expand, or adapt. For investors, this paints a steady picture for the future.Unlock 25+ Years of Financial Data
Get access to extended historical data, advanced metrics, and more with our premium plan